Background & objective: Of the many pharmacological options for the management of postpartum hemorrhage, oxytocin is the first line of treatment. The newer drug carbetocin is getting popularity among obstetricians, although there is as yet not enough evidence about its safety and efficacy. The present study attempted to compare oxytocin with carbetocin for the routine prevention of postpartum hemorrhage (PPH) following caesarean section. Methods: The present comparative clinical trial was conducted in the Department of Obstetrics and Gynaecology in Rajshahi Medical College Hospital (RMCH), Rajshahi over a period of one year between March 2017 to February 2018. Pregnant women undergoing cesarean section under regional anaesthesia and do not have known hypersensitivity to oxytocin and carbetocin and known bleeding disorders were included in the study. A total of 96 such subjects were consecutively included and were randomly assigned to either Oxytocin (n = 48) and Carbetocin (n = 48) Groups. The outcome was evaluated in terms of incidence of PPH (loss of blood > 1000 ml), blood transfusion needed to compensate for lost blood, additional oxytocics needed to manage PPH and adverse effects encountered by the subjects. Result: The mean age of the subjects was around 25 years and the age distribution between the study groups was almost similar. In terms of obstetric characteristics multigravida was predominant in the Oxytocin group than that in the Carbetocin group. The current pregnancy profile like gestational age, ANC received, number of foetus in utero and placental position all were comparable between the groups. Antenatal conditions/diseases deemed to have influence on PPH were no different between the study groups. Past history of caesarean section was higher in Oxytocin group (43.8%) than that in the Carbetocin group (22.9%). There were negligible incidences of past PPH and myomectomy in either group. The mean haemoglobin level in the former and the latter groups were 9.5 and 10 gm/dl respectively with majority of the subjects being mildly anaemic. More than 80% of the subjects in either group underwent emergency caesarean section. The outcome showed that 83% in the Oxytocin group and 90% in the Carbetocin group did not develop PPH, but the difference was not significant. The mean blood lost was somewhat lower in the carbetocin group (630 ml) than that in the Oxytocin group (685 ml). The number of patients needed to be transfused and the mean amount of blood transfused to them in each group was fairly comparable. Oxytocin group received additional oxytocic drugs, such as, Metherspan and Misoprostol more frequently than the Carbetocin group did, but the differences did not turn significant. A few patients in both groups developed adverse effects but they were comparable. The mean 24-hours urine output was > 2000 ml in either group). Conclusion: The study concluded that the incidence of PPH, the amount of blood lost, number of patients transfused, amount of blood transfused and the additional amount of oxytocics required for the prevention and treatment of PPH were broadly comparable between the two study groups. Ibrahim Card Med J 2021; 11 (1): 71-78
Background & objective: Although the role of vitamin-D in calcium metabolism and bone health is undisputed, other long-term health consequences of low vitamin-D are still debated. Observational studies have recently indicated that vitamin-D deficiency may be a modifiable risk factor for gestational diabetes mellitus (GDM), although several experimental studies have failed to establish such an association. The present study was undertaken to test the hypothesis that vitamin-D insufficiency or deficiency is associated with GDM. Methods: The present case-control study was conducted in the Department of Obstetrics and Gynaecology, Rajshahi Medical College (RMC), Rajshahi, Bangladesh, over a period of 1 year between July 2019 to June 2020. Patients with confirmed GDM (case) and normal pregnant women (control) attending in the above-mentioned place during the study period were the study population. A total of 18 cases and 54 controls were consecutively included in the study based on predefined eligibility criteria. The exposure and outcome variables were serum vitamin-D insufficiency/deficiency and GDM respectively. Vitamin D insufficiency was considered when serum level 25(OH)D ranges from ≥ 15 to < 30 ng/ml and deficiency was termed if 25(OH)D level lies below 15 ng/ml. Crosstab analysis with Odds Ratio (OR) was done to find the association between vitamin-D and GDM and the risk of developing the outcome (GDM) due to vitamin-D insufficiency or deficiency. Result: In the present study age, residence, socioeconomic status and season at data collection were almost identically distributed between case and control groups. However, the study demonstrated occupation, pre-pregnancy obesity, family history of type-II diabetes, polyhydramnios, level of hemoglobin and serum vitamin-D insufficiency/deficiency to be associated with GDM. Majority (83.3%) of the GDM patients had insufficient or deficient serum vitamin D level (< 30 ng/mL) as compared to 57.4% of the control group. The risk of having GDM in pregnant women with insufficient or deficient serum vitamin-D was estimated to be almost 4-fold (95% CI = 1.1 – 14.3) higher (p = 0.047) than that in the pregnant women with normal serum vitamin-D level. Conclusion: The study concluded that pregnant women with GDM are associated with insufficient or deficient serum vitamin-D with risk of having GDM in pregnant women with insufficient or deficient serum vitamin-D is much greater than the pregnant women with normal serum vitamin-D level. Ibrahim Card Med J 2021; 11 (1): 41-47
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.